Alliance Pharma says Isprelor results "inadequate"
Free email from MoneyWeek
Money
Morning is the FREE daily email from MoneyWeek – a punchy round-up
of the latest investment news and profit opportunities. DON’T MISS
IT!
This genius investor does dizzying levels of research to uncover...Half Price Shares!
Speciality pharmaceutical firm Alliance Pharma said results from Phase III trials of its labour induction drug Isprelor will be "inadequate" to support the application for registration.
"It now appears likely that results of the Phase III trials completed last year will be inadequate, alone, to support the application for registration," it said.
(Article continues below)Advertisement
The group said following discussions yesterday with the European regulatory authorities, it is re-evaluating its plan for Isprelor.
"As a result the company is re-assessing what additional work needs to be done, but it is now unlikely that the filing for registration will take place before 2011," it added.
FREE! For all our latest advice on making profitable investments, claim your 3-week FREE trial of the MoneyWeek website and magazine now.
Money Morning is the FREE daily email from MoneyWeek
– a punchy round-up of the latest investment news and profit opportunities.
DON’T MISS IT!
